RecruitingEarly Phase 1NCT07086794

Cocaine and Pentoxifylline (BED IN 47)

Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study With Pentoxifylline

Sponsor

William Stoops

Enrollment

30 participants

Start Date

Nov 10, 2025

Study Type

INTERVENTIONAL

Conditions

Cocaine Use Disorder

Summary

This will be a human laboratory study evaluating the influence of pentoxifylline treatment on the effects of cocaine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cocaine (IV), a drug called Pentoxifylline, and others for people with cocaine use disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

The effects of placebo will be determined.

DRUGCocaine (IV)

The effects of IV Cocaine will be determined.

DRUGPentoxifylline

The effects of pentoxifylline will be determined.

Locations(1)

Psychopharmacology of Addiction Laboratory

Lexington, Kentucky, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07086794

Related Trials

Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder

NCT055299271 location

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

NCT072279481 location